These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 27763956)

  • 1. Concentration of D-dimers in Bile-a Novel Marker of Pancreatic Cancer Enhancing Accuracy of Standard CA19-9 Measurement: Dual Test Hypothesis.
    Durczynski A; Kumor A; Grzelak P; Strzelczyk M; Hogendorf P; Poznanska G; Skulimowski A; Szymanski D; Strzelczyk J
    Pancreas; 2017 Jan; 46(1):e9-e10. PubMed ID: 27763956
    [No Abstract]   [Full Text] [Related]  

  • 2. MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
    Schultz NA; Dehlendorff C; Jensen BV; Bjerregaard JK; Nielsen KR; Bojesen SE; Calatayud D; Nielsen SE; Yilmaz M; Holländer NH; Andersen KK; Johansen JS
    JAMA; 2014 Jan 22-29; 311(4):392-404. PubMed ID: 24449318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutrophil Gelatinase-Associated Lipocalin (NGAL) concentration in urine is superior to CA19-9 and Ca 125 in differentiation of pancreatic mass: Preliminary report.
    Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
    Cancer Biomark; 2016 Mar; 16(4):537-43. PubMed ID: 27002756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis.
    Su SB; Qin SY; Chen W; Luo W; Jiang HX
    World J Gastroenterol; 2015 Apr; 21(14):4323-33. PubMed ID: 25892884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Verification of the effectiveness of fucosylated haptoglobin as a pancreatic cancer marker in clinical diagnosis.
    Kuwatani M; Kawakami H; Kubota Y; Kawakubo K; Ito YM; Togo S; Ikeda T; Kusama K; Kobayashi Y; Murata T; Sakamoto N
    Pancreatology; 2019 Jun; 19(4):569-577. PubMed ID: 31031206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The assessment of serum and diagnostic peritoneal lavage concentration of matrix metalloproteinase-2, matrix metalloproteinase-9, carbohydrate antigen 19-9, and carcinoembryonic antigen in patients with pancreatic cancer and chronic pancreatitis.
    Dranka-Bojarowska D; Lewinski A; Lekstan A; Gajda M; Ciosek J; Mrowiec S
    J Physiol Pharmacol; 2020 Oct; 71(5):. PubMed ID: 33571962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of matrix metalloproteinase 7 in plasma and pancreatic juice as a biomarker for pancreatic cancer.
    Kuhlmann KF; van Till JW; Boermeester MA; de Reuver PR; Tzvetanova ID; Offerhaus GJ; Ten Kate FJ; Busch OR; van Gulik TM; Gouma DJ; Crawford HC
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):886-91. PubMed ID: 17507610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical value of serum neopterin, tissue polypeptide-specific antigen and CA19-9 levels in differential diagnosis between pancreatic cancer and chronic pancreatitis.
    Talar-Wojnarowska R; Gasiorowska A; Olakowski M; Lekstan A; Lampe P; Malecka-Panas E
    Pancreatology; 2010; 10(6):689-94. PubMed ID: 21242708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection.
    Fahrmann JF; Schmidt CM; Mao X; Irajizad E; Loftus M; Zhang J; Patel N; Vykoukal J; Dennison JB; Long JP; Do KA; Zhang J; Chabot JA; Kluger MD; Kastrinos F; Brais L; Babic A; Jajoo K; Lee LS; Clancy TE; Ng K; Bullock A; Genkinger J; Yip-Schneider MT; Maitra A; Wolpin BM; Hanash S
    Gastroenterology; 2021 Mar; 160(4):1373-1383.e6. PubMed ID: 33333055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of serum D-dimer, fibrinogen, and CA19-9 for postoperative monitoring and survival prediction in resectable pancreatic carcinoma.
    Cao J; Fu Z; Gao L; Wang X; Cheng S; Wang X; Ren H
    World J Surg Oncol; 2017 Feb; 15(1):48. PubMed ID: 28219450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 protein expression and CA19.9 values in differential cytological diagnosis of pancreatic cancer complicated with chronic pancreatitis and chronic pancreatitis.
    Mu DQ; Wang GF; Peng SY
    World J Gastroenterol; 2003 Aug; 9(8):1815-8. PubMed ID: 12918127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Circulating MiR-25 as a Potential Biomarker for Pancreatic Cancer Diagnosis.
    Deng T; Yuan Y; Zhang C; Zhang C; Yao W; Wang C; Liu R; Ba Y
    Cell Physiol Biochem; 2016; 39(5):1716-1722. PubMed ID: 27639768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of pancreatic adenocarcinoma using circulating fragments of fibrinogen.
    Ward DG; Wei W; Buckels J; Taha AM; Hegab B; Tariciotti L; Salih R; Qi YQ; Martin A; Johnson PJ
    Eur J Gastroenterol Hepatol; 2010 Nov; 22(11):1358-63. PubMed ID: 20555269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease.
    Morris-Stiff G; Teli M; Jardine N; Puntis MC
    Hepatobiliary Pancreat Dis Int; 2009 Dec; 8(6):620-6. PubMed ID: 20007080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increase diagnostic accuracy in differentiating focal type autoimmune pancreatitis from pancreatic cancer with combined serum IgG4 and CA19-9 levels.
    Chang MC; Liang PC; Jan S; Yang CY; Tien YW; Wei SC; Wong JM; Chang YT
    Pancreatology; 2014; 14(5):366-72. PubMed ID: 25278306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum heat shock protein 27 is increased in chronic pancreatitis and pancreatic carcinoma.
    Liao WC; Wu MS; Wang HP; Tien YW; Lin JT
    Pancreas; 2009 May; 38(4):422-6. PubMed ID: 19214136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CA 19-9 to differentiate benign and malignant masses in chronic pancreatitis: is there any benefit?
    Bedi MM; Gandhi MD; Jacob G; Lekha V; Venugopal A; Ramesh H
    Indian J Gastroenterol; 2009; 28(1):24-7. PubMed ID: 19529898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The assessment of serum concentration of adiponectin, leptin and serum carbohydrate antigen-19.9 in patients with pancreatic cancer and chronic pancreatitis.
    Dranka-Bojarowska D; Lekstan A; Olakowski M; Jablonska B; Lewinski A; Musialski P; Sobczyk W; Kapalka A; Lampe P
    J Physiol Pharmacol; 2015 Oct; 66(5):653-63. PubMed ID: 26579571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multianalyte profiling of serum cytokines for detection of pancreatic cancer.
    Zeh HJ; Winikoff S; Landsittel DP; Gorelik E; Marrangoni AM; Velikokhatnaya L; Winans MT; Lee K; Moser A; Bartlett D; Lotze MT; Siegfried JM; Whitcomb D; Papacristou G; Slivka A; Bigbee WL; Lokshin AE
    Cancer Biomark; 2005; 1(6):259-69. PubMed ID: 17192050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CEACAM1, a novel serum biomarker for pancreatic cancer.
    Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
    Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.